R&D
Virtual R&D
ST Pharm Virtual R&D
Innovative virtual R&D strategy
It enables us to implement A&D (Acquisition & Development) and C&D (Connection & Development) so that we can achieve desirable results with low cost and high efficiency.
Collaboration
Incubation
New Drug
C&D
A&D
CxOs
ST Pharm’s New drug Pipeline
ST PHARM has world-class two pipelines
('First in class')
- 1Anti HIV /AIDS
First in class - 2Anti – cancer (colorectal)
First in class
Pipeline
(Indication)
(Indication)
Drug Class
Right /
Collaborator
Collaborator
Stage
Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3
STP0404
(Anti HIV /AIDS)
(Anti HIV /AIDS)
Small molecule
Emory Univ.
Colorado State Univ.
Colorado State Univ.
- HIV Integrase Inhibitor
STP1002
(Anti–cancer, colorectal)
(Anti–cancer, colorectal)
Small molecule
Asan Hospital (KOREA)
- Tankyrase Inhibitor
STP2104
(Vaccine, COVID-19)
(Vaccine, COVID-19)
mRNA
Fully-owned
STP2130
(Vaccine, COVID-19)
(Vaccine, COVID-19)
mRNA
Fully-owned
NASH
Small molecule
Korea Research Institute of Chemical technology
Oral Heparin
Macromolecule
SNU (KOREA) B&L Deli Pharm
- Deep vein thrombosis
- Cancer-associated thrombosis
Influenza Virus
Small molecule
KRICT
Anti – virus
Small molecule
Oncocross
Others
Small molecule
Undisclosed